• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Percent of Office of In Vitro Diagnostics and Radiological Health (OIR) intra- and inter-Office eConsults completed on time during the month

Dictionary: CDRH uses the internal expert consultation process to acquire information and analysis on issues related to medical devices. Intra- and inter-office consultations are completed for a variety of work products requiring expertise within and across CDRH offices, including premarket device submissions, post-approval studies, and compliance and enforcement actions. Inter-office eConsults are used to facilitate the exchange of scientific information and staff expertise across CDRH, critical to making well-supported regulatory decisions. eConsult is the system CDRH uses to manage and monitor expert consult requests.

Information is current as of September 30, 2013

Fiscal Year - 2011

Skip graphic and jump to text data

TimeTargetPercent
Oct 20108593
Nov 20108593
Dec 20108592
Jan 20118596
Feb 20118596
Mar 20118595
Apr 20118596
May 20118595
Jun 20118596
Jul 20118595
Aug 20118597
Sep 20118595

FY 2011 Overall: 95%

Number of OIR intra- and inter-Office eConsults completed on time during the month

Fiscal Year - 2011
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2010N/A153
Nov 2010N/A171
Dec 2010N/A201
Jan 2011N/A212
Feb 2011N/A189
Mar 2011N/A287
Apr 2011N/A252
May 2011N/A292
Jun 2011N/A326
Jul 2011N/A218
Aug 2011N/A266
Sep 2011N/A228

FY 2011 Total: 2,795

Total number of OIR intra- and inter-Office eConsults completed during the month

Fiscal Year - 2011
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2010N/A165
Nov 2010N/A183
Dec 2010N/A218
Jan 2011N/A221
Feb 2011N/A197
Mar 2011N/A302
Apr 2011N/A263
May 2011N/A307
Jun 2011N/A339
Jul 2011N/A229
Aug 2011N/A275
Sep 2011N/A240

FY 2011 Total: 2,939

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.